By AuntMinnieEurope.com staff writers
February 26, 2019

iCAD plans to highlight its artificial intelligence (AI) software for digital breast tomosynthesis (DBT), ProFound AI, at the upcoming ECR 2019 in Vienna.

The software was cleared on 7 December 2018 by the U.S. Food and Drug Administration (FDA). It detects malignant soft-tissue densities and calcifications while offering radiologists scoring information that indicates the likelihood that a detection or case is malignant, the company said.

At the meeting, iCAD will also preview ProFound AI for 2D mammography, currently pending the CE Mark.

iCAD highlights study results of DBT software
Computer-aided detection (CAD) developer iCAD is touting the results of a new study using its digital breast tomosynthesis (DBT) cancer detection software....
iCAD gets CE Mark for PowerLook Tomo
iCAD has received the CE Mark for its PowerLook Tomo Detection 2.0 deep-learning computer-aided detection software for digital breast tomosynthesis.
iCAD system treats 1st patient in Australia
Computer-aided detection (CAD) developer iCAD said the first early-stage breast cancer patient was treated in Australia with intraoperative radiation...

Copyright © 2019 AuntMinnieEurope.com

Last Updated np 2/25/2019 4:27:33 PM